. 2021 Aug 27;2(9):100383. doi: 10.1016/j.xcrm.2021.100383

Table 2.

Treatment-related adverse events

	80 mg (n = 39)			120 mg (n = 3)
Adverse events	<Grade 3	≥Grade 3	Total	<Grade 3	≥Grade 3	Total
Total		15 (38.5%)	37 (94.9%)		3 (100.0%)	3 (100.0%)
Hand-foot syndrome	16 (41.0%)	4 (10.3%)	20 (51.3%)	1 (33.3%)	2 (66.7%)	3 (100.0%)
Rash	10 (25.6%)	2 (5.1%)	12 (30.8%)	1 (33.3%)	0 (0.0%)	1 (33.3%)
Fever	8 (20.5%)	0 (0.0%)	8 (20.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hoarseness	7 (17.9%)	0 (0.0%)	7 (17.9%)	2 (66.7%)	0 (0.0%)	2 (66.7%)
Diarrhea	6 (15.4%)	1 (2.6%)	7 (17.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypertension	5 (12.8%)	1 (2.6%)	6 (15.4%)	0 (0.0%)	2 (66.7%)	2 (66.7%)
Impaired liver function	2 (5.1%)	4 (10.3%)	6 (15.4%)	0 (0.0%)	1 (33.3%)	1 (33.3%)
Chest distress	6 (15.4%)	0 (0.0%)	6 (15.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Myalgia	5 (12.8%)	0 (0.0%)	5 (12.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Headache	3 (7.7%)	2 (5.1%)	5 (12.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Thrombocytopenia	3 (7.7%)	1 (2.6%)	4 (10.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Fatigue	4 (10.3%)	0 (0.0%)	4 (10.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Abdominal pain	3 (7.7%)	0 (0.0%)	3 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Proctorrhagia	3 (7.7%)	0 (0.0%)	3 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Bilirubin elevated	1 (2.6%)	2 (5.1%)	3 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Leukocytosis	1 (2.6%)	0 (0.0%)	1 (2.6%)	1 (33.3%)	0 (0.0%)	1 (33.3%)
Hemoglobin reduction	2 (5.1%)	0 (0.0%)	2 (5.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Decreased appetite	2 (5.1%)	0 (0.0%)	2 (5.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Frequent premature ventricular	2 (5.1%)	0 (0.0%)	2 (5.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Proteinuria	1 (2.6%)	0 (0.0%)	1 (2.6%)	1 (33.3%)	0 (0.0%)	0 (0.0%)
Pruritus	1 (2.6%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	1 (33.3%)	1 (33.3%)
Hypothyroidism	1 (2.6%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hyperthyroidism	1 (2.6%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neutropenia	0 (0.0%)	1 (2.6%)	1 (2.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Use of glucocorticoids			4 (10.3%)			0 (0.0%)